Brenntag and Seqens partner exclusively in Europe to expand access to high-quality, reliable non-GMP pharmaceutical intermediates for research and development.
Brenntag, the global leader in chemical and ingredient distribution, has announced a strategic sole distribution partnership with Seqens for the supply of non-GMP pharmaceutical intermediates across Europe. This agreement marks an important step in strengthening the availability of specialized intermediates for pharmaceutical research, development, and early-stage manufacturing throughout the region.
In the pharmaceutical value chain, the role of high-quality intermediates is fundamental. Each phase of chemical synthesis—whether it involves introducing functional groups, performing coupling reactions, or modifying molecular structures—depends heavily on intermediates that meet precise technical specifications. Equally important is the accompanying documentation, which must align with stringent industry expectations. Any deviation in quality or traceability can compromise efficiency, timelines, and ultimately the success of pharmaceutical innovation.
Through this sole distribution agreement, Brenntag gains the exclusive right to distribute a portfolio of non-GMP intermediates produced by Seqens, a globally recognized contract development and manufacturing organization (CDMO) and ingredient manufacturer. This collaboration enables Brenntag to deliver these high-quality products to a wide and diverse customer base across Europe, helping pharmaceutical and life sciences companies optimize their synthetic pathways and research processes.
Seqens brings to the partnership a strong reputation for reliability, competitiveness, and technical excellence. Its non-GMP intermediates portfolio is designed to support customers during the early and intermediate stages of drug development, where flexibility, responsiveness, and consistent quality are essential. By working with Brenntag, Seqens can further enhance its reach in the European market while ensuring that customers benefit from optimized lead times and adaptable supply solutions.
For Brenntag customers, the partnership translates into several tangible advantages. These include access to deep regulatory expertise, robust quality standards, and a secure, transparent supply chain with production based in Europe. Brenntag’s established logistics infrastructure and commercial network will ensure improved product availability and broader geographic coverage, allowing customers to source critical intermediates efficiently and reliably. The collaboration also reinforces Brenntag’s role as a trusted partner capable of supporting pharmaceutical companies throughout the research and development lifecycle.
Commenting on the agreement, Joakim Rehné, Regional President Brenntag Pharma EMEA, highlighted the strategic importance of the partnership. He noted that the collaboration with Seqens represents a significant milestone in Brenntag’s ongoing commitment to the pharmaceutical sector. By expanding its portfolio with high-quality non-GMP intermediates, Brenntag aims to better support customers at every stage of their research activities. He also emphasized that integrating Seqens’ technical expertise and experienced teams into Brenntag’s partner network will create new opportunities for growth and future joint projects.
From Seqens’ perspective, the agreement aligns closely with its long-term strategic objectives. Alexandra Ngawa Zenang, Business Line Manager Pharma at Seqens, explained that the partnership reflects the company’s ambition to remain close to its customers while reinforcing its presence in Europe. By leveraging Brenntag’s distribution capabilities, Seqens can respond more rapidly to evolving market demands without compromising its high standards of quality, safety, and compliance.
Overall, the partnership between Brenntag and Seqens underscores a shared commitment to supporting pharmaceutical innovation in Europe. By combining Seqens’ manufacturing excellence with Brenntag’s distribution strength, the agreement is set to enhance supply reliability, flexibility, and customer access to critical non-GMP pharmaceutical intermediates across the region.
